|
Synonyms: AGEN-1181 | AGEN1181
Compound class:
Antibody
Comment: Botensilimab (AGEN-11810) is a Fc-enhanced anti-CTLA-4 monoclonal antibody [5]. It is proposed as an immuno-oncology agent for the treatment of poorly immunogenic and treatment refractory cancers [4,8]. Heavy and light chain peptide sequences for botensilimab are claimed in patent US10912831B1 [9], nominally SEQ IDs 25 and 27 respectively, and these are the chains of clone AGEN1884.H3 therein.
|
| References |
|
1. Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C et al.. (2018)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell, 33 (4): 649-663.e4. [PMID:29576375] |
|
2. Bengala E, Santini D, Picone V. (2026)
Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care. Immunooncol Technol, 29: 101558. [PMID:41502912] |
|
3. Bullock AJ, Schlechter BL, Fakih MG, Tsimberidou AM, Grossman JE, Gordon MS, Wilky BA, Pimentel A, Mahadevan D, Balmanoukian AS et al.. (2024)
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat Med, 30 (9): 2558-2567. [PMID:38871975] |
|
4. Chand D, Savitsky DA, Krishnan S, Mednick G, Delepine C, Garcia-Broncano P, Soh KT, Wu W, Wilkens MK, Udartseva O et al.. (2024)
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy. Cancer Discov, 14 (12): 2407-2429. [PMID:39083809] |
|
5. Delepine C, Levey D, Krishnan S, Kim KS, Sonabend A, Wilkens M, Tanne A, Garcia-Brocano P, Galand C, Han H et al.. (2022)
470 Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and I-O refractory tumors. J Immunother Cancer, 10: A490–A490. DOI: 10.1136/jitc-2022-SITC2022.0470 |
|
6. Kasi PM, Hidalgo M, Jafari MD, Yeo H, Lowenfeld L, Khan U, Nguyen ATH, Siolas D, Swed B, Hyun J et al.. (2023)
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer. Oncogene, 42 (44): 3252-3259. [PMID:37731056] |
|
7. Porter R, Bockorny B, Corr BR, Mahadevan D, Wilky BA, El-Khoueiry AB, Bullock AJ, Hafez N, Moser J, Martynova A et al.. (2025)
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer. J Immunother Cancer, 13 (12). [PMID:41436232] |
|
8. Rudqvist NP, Avagyan M, Chand D. (2023)
Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy. Oncoimmunology, 12 (1): 2275333. [PMID:37937212] |
|
9. van Dijk M, Mundt CA, Ritter G, Schaer D, Wolchok JD, Merghoub T, Wilson NS, Savitsky DA, Finseis MA, Underwoo DJ et al.. (2021)
Anti-CTLA-4 antibodies and methods of use thereof. Patent number: US10912831B1. Assignee: Ludwig Institute for Cancer Research Ltd Memorial Sloan Kettering Cancer Center, Agenus Inc. Priority date: 24/09/2020. Publication date: 09/02/2021. |
|
10. Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, Agulnik M, Singh A, Mahadevan D, Stebbing J et al.. (2025)
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas. J Clin Oncol, 43 (11): 1358-1368. [PMID:39869830] |